Home/Pipeline/ETH47 (with Vertex)

ETH47 (with Vertex)

Cystic Fibrosis

Pre-clinical/Phase 1Active

Key Facts

Indication

Cystic Fibrosis

Phase

Pre-clinical/Phase 1

Status

Active

Company

Ethris

About Ethris

Ethris is a clinical-stage biotech specializing in mRNA therapeutics for respiratory diseases, utilizing its proprietary SNIM® RNA and LNP delivery platform. The company's lead programs target rare genetic disorders like cystic fibrosis and primary ciliary dyskinesia, with a broader pipeline exploring applications in viral defense and chronic lung diseases. As a private company, Ethris has secured significant partnerships with major pharmaceutical players like AstraZeneca and Vertex Pharmaceuticals, positioning it as a key innovator in localized mRNA delivery beyond systemic vaccines.

View full company profile

Therapeutic Areas

Respiratory Diseases Genetic Disorders Viral Infections

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active
KIT2014	Kither Biotech	Phase 2	Active